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Abstract
Background: It is still unclear whether addition of calcium/vitamin D supplements leads to an incremental
benefit in patients taking bisphosphonates and whether achievement of serum level of 25 (OH) vitamin D
of at least 70 nmol/L has an impact on the skeletal response to bisphosphonates. Moreover the
maintenance of BMD after bisphosphonates withdrawal with the continuation of calcium/vitamin D
supplements only, remains uncertain. The aims were to assess the impact of vitamin D status on changes
in bone mineral density (BMD) in firstly patients with post-menopausal osteoporosis on bisphosphonates
and secondly following discontinuation of bisphosphonates after long-term use.
Methods: Two patient groups were recruited. The first study population comprised of 112 women
treated with a bisphosphonate. The second study population consisted of 35 women who had been on
bisphosphonates for > 5 years in whom the treatment agent was discontinued. Baseline BMD, changes in
BMD following treatment, duration of treatment, serum 25 (OH) vitamin D, parathyroid hormone (PTH),
urine C-terminal telopeptides of type 1 collagen (CTX) were obtained on the study participants.
Results: In the first study group, subjects with serum vitamin D concentrations (> 70 nmol/L) had a
significantly lower serum PTH level (mean [SEM] 41 [2] ng/L). PTH concentrations of 41 ng/L or less was
associated with a significantly higher increase in BMD at the hip following treatment with bisphosphonates
compared to patients with PTH > 41 ng/L (2.5% [0.9] v/s -0.2% [0.9], P = 0.04). In the second study group,
discontinuation of bisphosphonate for 15 months after long-term treatment did not result in significant
bone loss at the lumbar spine and total hip, although a trend towards gradual decline in BMD at the femoral
neck was observed.
Conclusion: the data suggest that optimal serum 25 (OH) vitamin D concentration may lead to further
reduction in bone loss at the hip in patients on bisphosphonates. A prospective controlled trial is needed
to evaluate whether the response to bisphosphonates is influenced by vitamin D status. BMD is preserved
at the lumbar spine and total hip following discontinuation of bisphosphonate for a short period following
long-term treatment, although a gradual loss occurs at the femoral neck.
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Background
Bisphosphonates are widely used in the treatment of oste-
oporosis and prevention of osteoporosis-related fractures.
The efficacy of these anti-resorptive agents has been exten-
sively studied in several randomised controlled trials
[1,2]. In all published clinical trials, calcium and vitamin
D supplements have also been used with the bisphospho-
nates as adjunctive therapy. Large scale studies have
shown that vitamin D supplementation between 700 and
800 I.U/day leads to a reduction in the risk of hip fracture
and non-vertebral fractures by 30% in adults older than
65 years [3], although recent trials have shown that vita-
min D, either alone or in combination with calcium sup-
plementation was ineffective in the primary or secondary
prevention of fractures in community-dwelling older peo-
ple [4,5]. However in the RECORD study [4], concentra-
tions of 25 (OH) vitamin D were measured only in a very
small subset of the patients. Therefore the vitamin D sta-
tus of the majority of participants was unknown. Low
serum concentrations of vitamin D is widespread in the
U.K [6] and moderate vitamin deficiency in older people
results in poor bone and muscle strength [7,8]. Serum 25
(OH) vitamin D concentrations that correlate with clini-
cally significant effects on muscle function and fracture
prevention is at least 70 nmol/L [9]. It is still unclear
whether addition of calcium/vitamin D supplements
leads to an incremental benefit in patients taking bisphos-
phonates and whether achievement of serum level of vita-
min D of at least 70 nmol/L has an impact on the skeletal
response to bisphosphonates.
Bisphosphonates including Alendronate, Etidronate and
Risedronate have a long retention time in bone and there
are some concerns about their long-term effects on skele-
tal mineralization [10]. Recent studies, including the frac-
ture intervention trial have shown that Alendronate,
administered for up to 10 years is safe and has continued
benefit on the skeleton [11]. The data also show that dis-
continuation of long-term (5 years or more) Alendronate
therapy results in minimal bone loss at the spine, suggest-
ing persistence of Alendronate's effects on bone. However
discontinuation of Alendronate seems to lead to gradual
loss of effect at the femoral neck and hip [11] although
data outside the confines of the randomised controlled
trial setting data are lacking. Thus the partial maintenance
of bisphosphonates effects after their withdrawal with the
continuation of calcium/vitamin D supplements only
remains uncertain in routine clinical practice. This is of
practical value particularly in patients where compliance
is an issue.
The aim of the study was to (1) determine the effect of
optimum serum concentrations (> 70 nmol/L) of 25(OH)
vitamin D on the skeletal response in patients treated with
bisphosphonates and (2) assess changes in bone mineral
density (BMD) following 12–18 months withdrawal of
Etidronate or Alendronate in long-term users (> 5 years)
with the continuation of calcium/vitamin D supplements
in post-menopausal osteoporosis, in the practical setting
of a metabolic bone clinic service.
Methods
Study Protocol
Subjects
The study is in 2 parts and investigates the influence of
vitamin D status on BMD response during treatment with
bisphosphonates and after withdrawal of bisphospho-
nates following long-term treatment. The first part of the
study consisted of a survey of 112 post-menopausal
women seen at the metabolic bone clinic consecutively
for review at Guy's Hospital, London U.K. They were all
being followed-up for assessment of their treatment
response after bisphosphonate treatment had been insti-
tuted in the metabolic bone clinic. The subjects were
recruited during their follow-up visit from April 2004 to
January 2005 at the clinic. BMD had been measured at
baseline prior to treatment and at their follow-up visit.
The majority of patients had been referred from primary
care for the management of post-menopausal osteoporo-
sis. They were all treated with a bisphosphonate with an
average duration of treatment of 3.8 years. The percentage
change in BMD from baseline following treatment was
calculated at the lumbar spine and the total hip following
a mean duration of 3.8 years between measurements.
Information on the age of menarche, menopausal age,
amount of alcohol consumption, smoking habits, level of
exercise, family history of osteoporosis, and history of
falls and fractures was obtained on all subjects at consul-
tation. None of the subjects were receiving hormone
replacement therapy. As part of routine clinical practice,
(1) DEXA scans were carried out to measure BMD at the
spine and hip (2) X-rays of the thoracolumbar spine were
done on all patients to document any vertebral fractures
and (3) measurement of serum parathyroid hormone
(PTH), 25(OH) vitamin D were carried out on the same
day. A random urine sample for the measurement of urine
C-terminal telopeptides of type 1 collagen (CTX), a
marker of bone resorption, was also obtained on the
patients at their clinic visit. The patients demographics are
summarised in table 1.
The second part of the study looked at the effect of
bisphosphonates withdrawal with the continuation of
calcium/vitamin D supplements in subjects who had been
on bisphosphonates long-tern (>5 years). The study pop-
ulation in the second part of the study comprised of 35
post-menopausal women aged (mean [SEM]) 66.7 [2.1]
years who had been on long-term treatment (6.3 [0.32]
years) with a bisphosphonate (Etidronate or Alendronate)
and in whom treatment was discontinued for 12–18BMC Musculoskeletal Disorders 2007, 8:3 http://www.biomedcentral.com/1471-2474/8/3
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months. Of these, 54.3% (n = 19) were on Etidronate
(Didronel PMO) and 45.7% (n = 16) on Alendronate (10
mg daily or 70 mg weekly). After withdrawal of bisphos-
phonate, all patients were maintained on 1 g calcium and
800 I.U cholecalciferol daily (Calcichew D3 Forte, 2 tab-
lets daily). They were seen at 12–18 months (mean 15
months) after bisphosphonate was discontinued when
BMD at the spine, hip and femoral neck was re-assessed.
Analytical methods
Bone mineral density (BMD) was measured at the lumbar
spine and hip by dual-energy X-ray absorptiometry
(DEXA) (QDR 4500, Hologic, Waltham, MA, USA).
Instrument quality control was assessed by daily scanning
of a spine phantom. The co-efficient of variation (C.V) for
the in vivo BMD measurements were 1 % at the lumbar
spine and total hip. Body mass index (BMI) was calculated
using weight and height.
Haemoglobin, serum electrolytes, urea, creatinine, albu-
min, calcium and phosphate were measured by standard
laboratory procedures on the Beckman LX 20 analyser
(Beckman Coulter, Fulterton, CA, USA). Serum PTH was
measured on the Nicholas Advantage (Nicholas Institute,
Diagnostic Ltd. Essex, UK) by a chemiluminometric assay.
The reference range of the assay is 10–65 ng/L. Serum 25
(OH) vitamin D was determined by radioimmunoassay
(RIA) using a commercial kit following a rapid extraction
procedure (Diasorin, Still water, Minnesota, USA). The
assay reference range is 40–195 nmol/L. The inter-assay
CV's for serum PTH and 25 (OH) vitamin D were 4.1%
and 8.2% respectively at PTH concentrations of 17 ng/ml
and 25 (OH) vitamin D concentrations of 57 nmol/L.
Urine CTX was determined on a single random urine sam-
ple obtained at the clinic visit by an enzyme-linked immu-
nosorbent assay (Urine Crosslaps, Nordic Bioscience
Diagnostics A/S, Denmark). The results were expressed
after normalization to creatinine excretion. The reference
range derived from pre-menopausal women was 45–1035
μg/mmol creatinine. Inter-assay variation was < 10%.
Statistical analysis
Comparisons in absolute and percentage change in BMD
between groups based on their vitamin D status and
serum PTH concentrations and after discontinuation of
long-term bisphosphonates were made using two-tailed t-
tests. All values are given as the mean ± SEM, unless stated.
Univariate linear regression analyses were carried out
between serum PTH and 25 (OH) vitamin D, serum PTH,
vitamin D status and changes in lumbar spine and hip
BMD. Two-tailed p-value of < 0.05 was considered signif-
icant.
Results
Effect of vitamin D status during bisphosphonate 
treatment
In the first part of the study, the population comprised of
112 consecutive patients on bisphosphonates. Thirty
(27.4%), 64 (57.4%) and 38 (33%) patients had previ-
ously been or were still on Etidronate, Alendronate and
Risedronate respectively. Serum 25 (OH) vitamin D
results were available on 106 subjects only. The serum
concentration was less than 70 nmol/L in 53% (n = 56) of
patients (mean [SEM] serum concentrations: 50 [1.9]
nmol/L. The serum vitamin D concentrations were higher
than 70 nmol/L in 47% (n = 50) of subjects (mean [SEM]:
93 [3.3] nmol/L). Ten percent of patients(n = 11) had
serum concentrations below 40 nmol/L. PTH concentra-
tions were significantly lower in subjects with optimum
serum vitamin D (> 70 nmol/l) (PTH (vitamin D suffi-
cient group): 41 [2] ng/L v/s vitamin D insufficient group:
61.7 [5.3], p < 0.0001). However in a minority of patients
(n = 20) with vitamin D concentrations <70 nmol/L
(mean [SEM] 54 [2.5] nmol/L), serum PTH was less than
41 ng/L (mean [SEM] 30 [2.8].
The patients were divided into 2 groups based on their
serum PTH concentrations. The cut-off level used was 41
ng/L which corresponded to the mean serum PTH concen-
trations in the vitamin D sufficient group. PTH was below
41 ng/L in 45% (n = 48) of subjects only (Figure 1). There
were no statistically significant differences between the 2
groups with respect to age, BMI, menopausal age, physical
activity, type of bisphosphonate and length of treatment.
No significant differences in baseline BMD (mean [SD])
at either the lumbar spine or total hip between the 2 sub-
groups were observed (patients with serum PTH < 41 ng/
L: LS BMD 0.738 [0.098], Total Hip (TH) BMD 0.716
Table 1: Summary of patient demographics and clinical/
biochemical characteristice (n = 112). All data are expressed as 
mean (SEM) and number (percentages).
Reference ranges
Age (years) 68.4 ± 0.87
Age at menopause (years) 46.6 ± 0.56
BMI (kg/m 2) 24.2 ± 0.43
Current smokers (%) 21 (18.6)
Alcohol intake ≤ 14 units/week (%) 52 (46.4)
Previous fragility Fracture (s) (%) 68 (60.7)
Family history of osteoporosis (%) 27 (24.1)
Family history of fracture (%) 20 (17.9)
History of falls (%) 31 (27.7)
Formal exercise (%) 37 (33.0)
Walking (≥ 30 minutes/day) (%) 26 (50.9)
Bisphosphonate treatment duration (years) 3.81 ± 0.28
Serum Calcium (nmol/l) 2.43 ± 0.01 2.2–2.6
Serum 25(OH) vitamin D (nmol/l) 70.6 ± 2.86 40–195
Serum Parathyroid Hormone (ng/l) 51.6 ± 3.12 10–65
Urine CTX (μg/mmol creatinine) 151.3 ± 
16.43
45–
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[0.11], serum PTH >41 ng/L: LS BMD .749 [0.12], TH
BMD 0.712 [0.01], Patients with serum 25 (OH) vitamin
D >70 nmol/L: LS BMD 0.738 [0.1], TH BMD 0.71 [0.12],
serum 25 (OH) vitamin D < 70 nmol/L: LS BMD 0.75
[0.12], TH BMD 0.714 [0.09]). There was no significant
difference in percentage increase or absolute change in
lumbar spine BMD following bisphosphonate treatment
between the 2 groups (Patients with serum PTH < 41 ng/
L: % change in BMD 5.4 [1.13], serum PTH > 41 ng/L:
5.45 [0.8]). In the patients with lower serum PTH and
optimum vitamin D concentrations, hip BMD improved
by 2.5%. A significant difference in the changes in BMD at
the hip was seen between the 2 groups as shown in Figure
1. The absolute changes in BMD between the 2 groups
were also significant (Patients with serum PTH < 41 ng/L:
0.014 [0.006], serum PTH > 41 ng/L: -0.0002 [0.005] g/
cm2, p < 0.05). A similar trend in the percentage and abso-
lute changes in BMD at the hip was observed when com-
paring BMD changes between the women according their
serum 25 (OH) vitamin D concentrations using the opti-
mum cut-off level of 70 nmol/L (9) (Figure 2), (Patients
with serum 25 (OH)D < 70 nmol/L: -0.004 [0.007],
serum 25 (OH)D >70 nmol/L: 0.01 [0.004] g/cm2, p =
0.06) although the results failed to reach statistical signif-
icance. There was no significant difference in urine CTX
between the patients based on their PTH concentrations
(PTH < 41 ng/L: 148 [29], PTH > 41 ng/L: 162 [23], p =
0.7).
A strong negative correlation was seen between serum
PTH and 25 (OH) vitamin D (r = -0.33, p < 0.0001). Small
but significant correlations were observed between the %
changes in lumbar spine and hip BMD and PTH concen-
trations (LS BMD: r = -0.22, p < 0.05, Total hip BMD; r = -
0.24, p < 0.05) Figures 3 and 4.
Effect of bisphosphonate withdrawal with continuation of 
calcium/vitamin D supplements only on BMD
In the second study population (n = 35) where bisphos-
phonates was discontinued for 12–18 months after long-
term treatment (> 5 years), BMD increased significantly at
all sites from baseline up until the time of discontinua-
tion. The mean percentage increase in BMD during treat-
ment was: LS 8.9 [0.89] %, FN 3.5 [0.06] %, TH 4.4
[0.054] %. Following discontinuation for 12–18 months,
there was no significant change in BMD at the lumbar
spine and total hip (BMD at discontinuation vs. BMD
after discontinuation): LS 0.832 [0.019] vs. 0.831 [0.018]
p = 0.809; TH 0.769 [0.021] vs. 0.765 [0.019] p = 0.372 as
illustrated in Figures 5 and 6. However, a small reduction
in BMD was observed at the femoral neck (FN 0.635
[0.015] vs. 0.627 [0.014] p = 0.094) as shown in Figure 7.
Age, body mass index (BMI) and the existence of previous
fractures had no effect on the BMD response to bisphos-
phonate withdrawal. None of the patients sustained a new
fracture, although we cannot exclude non-symptomatic
vertebral fractures, during the 15 months period off ther-
apy. There was no significant change in BMD after discon-
tinuation in any of the measured sites between patients on
etidronate and alendronate, although the patients on
Percentage change in BMD from baseline during bisphospho- nate treatment at the lumbar spine and total hip in the study  population divided into 2 groups based on their serum 25  (OH) D concentration (cut-off value: 70 nmol/L) Figure 2
Percentage change in BMD from baseline during bisphospho-
nate treatment at the lumbar spine and total hip in the study 
population divided into 2 groups based on their serum 25 
(OH) D concentration (cut-off value: 70 nmol/L). The % 
change in BMD at the hip was less in the group with sub-opti-
mal vitamin D. Values are shown as the mean [SEM], # p = 
0.08.
25 (OH) D : 93 [3.3] nmol/L  25 (OH) D : 50 [1.9] nmol/L 
# 
Percentage change in BMD from baseline during bisphospho- nate treatment at the lumbar spine and total hip in the study  population divided into 2 groups based on their serum PTH  concentration (cut-off value: 41 ng/L) Figure 1
Percentage change in BMD from baseline during bisphospho-
nate treatment at the lumbar spine and total hip in the study 
population divided into 2 groups based on their serum PTH 
concentration (cut-off value: 41 ng/L). A significant difference 
in % change in BMD at the hip was observed between the 2 
groups. Values are shown as the mean [SEM], * p < 0.05.
PTH : 30 [1.2]   PTH : 65 [3.5]  BMC Musculoskeletal Disorders 2007, 8:3 http://www.biomedcentral.com/1471-2474/8/3
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Etidronate had been treated for a longer period (p =
0.029) (Table 2).
Discussion
Serum 25 (OH) vitamin D has been the generally accepted
indicator of vitamin D status but there is no uniform con-
sensus on which serum values constitute sufficiency. A
number of studies have indicated optimal 25 (OH) vita-
min D levels as that required to reduce PTH and bone
turnover and values range from 50 nmol/l to 80 nmol/l
[12,13]. The threshold for serum 25 (OH) vitamin D con-
centrations which correlate with optimal bone and musc-
The relationship between percentage change in BMD at the total hip and PTH concentrations Figure 4
The relationship between percentage change in BMD at the total hip and PTH concentrations.
-25
-20
-15
-10
-5
0
5
10
15
20
25
0 50 100 150 200
PTH (ng/L)
%
 
c
h
a
n
g
e
 
i
n
 
h
i
p
 
B
M
D r = - 0.24 
p < 0.05 
The relationship between percentage change in BMD at the Lumbar spine and PTH concentrations Figure 3
The relationship between percentage change in BMD at the Lumbar spine and PTH concentrations.
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uloskeletal function and reduction in fracture risk in the
elderly population has been shown to be at least 70 nmol/
l [14].
Recent guidelines recommend that patients receiving
treatment for osteoporosis should be calcium and vitamin
D replete. Bisphosphonates are well established in the
treatment of post-menopausal osteoporosis and fracture
prevention. Vitamin D insufficiency may affect the
response to anti-resorptive therapy in terms of improve-
ment in BMD as the reduction in bone turnover and min-
eralization process may be impaired. However, evidence
for this is lacking particularly with the newer bisphospho-
nates and merits investigation in the light of recent epide-
miological findings of widespread low serum vitamin D
levels in the elderly population [6,7]. There are no clear
clinical decision limits for serum 25 (OH) vitamin D con-
centrations for optimization of bisphosphonates
response. Our data show that BMD response to bisphos-
phonates, at the hip site is impaired in patients who have
a PTH level of > 41 ng/L which correlate with a 25 (OH)
vitamin D level of < 70 nmol/l. This would be in keeping
with loss of predominantly cortical bone which is more
commonly associated with high PTH levels. The lack of
difference in urine CTX between the 2 groups may be
explained, at least in part, by firstly the variability in uri-
nary measurement as we obtained only a single measure-
ment in clinic and secondly bone turnover may be
underestimated as the urine samples were non-fasting.
Another explanation is that trabecular bone which has a
larger surface area than cortical bone is not affected to the
same extent. Our findings are in contrast to previous
observations with other anti-resorptive agents like
raloxifene [15]. Vitamin D insufficiency did not impair
the BMD response to raloxifene. This effect may be in part
due to raloxifene's ability to increase calcium absorption
via its selective oestrogen receptor effects on the intestine,
unlike the bisphosphonates. Indeed dietary calcium
intake independent of vitamin D status may also regulate
PTH. This may explain, at least in part, the findings of a
low serum PTH (< 41 ng/ml) in some of our patients with
sub-optimum vitamin D (< 70 nmol/L). Bisphosphonates
increase bone strength by preventing bone resorption,
thus reducing trabecular perforation and cortical porosity
and improving bone mineralization as bone remodeling
Changes in BMD at the lumbar spine following discontinua- tion of bisphosphonates for 12–18 months after long-term  use Figure 5
Changes in BMD at the lumbar spine following discontinua-
tion of bisphosphonates for 12–18 months after long-term 
use.
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Table 2: Summary of patient characteristics and demographics and change in BMD following discontinuation of etidronate or 
alendronate.
Didronel PMO (n = 19) Fosamax (n = 16)
Age at Discontinuation (mean [SD]) 64.3 [14.41] 69.4 [9.23]
Years on Treatment (mean [SD]) 6.8 [2.21] 5.6 [1.03] *
Age at Menarche (mean [SD]) 13.0 [1.664] 12.8 [2.49]
Number of years since menopause (mean [SD]) 24.7 [9.18] 27.36 [9.04]
Milk Intake ≥ 1/2 pint/day (%) 15.8 6.25
Walking < 30 minutes/day 36.48 25
(%) > 1 hour/day 5.26 12.5
Previous fragility fracture(s) (%) 26.32 37.5
BMI (Kg/m2) (mean [SD]) 25.47 [6.27] 26.48 [4.67]
Current and Ex-Smokers (%) 36.84 18.75
Alcohol Intake ≤ 14 units/week (%) 52.63 37.5
Positive Family History of Osteoporosis (%) 42.12 25
Lumbar Spine BMD at discontinuation (g/cm2) (mean [SD]) 0.856 [0.118] 0.761 [0.106]
Lumbar Spine BMD after discontinuation (g/cm2) (mean [SD]) 0.855 [0.107] 0.769 [0.106]
Total Hip BMD at discontinuation (g/cm2) (mean [SD]) 0.794 [0.133] 0.739 [0.105]
Total Hip BMD after discontinuation (g/cm2) (mean [SD]) 0.792 [0.129] 0.736 [0.099]
* p = 0.029BMC Musculoskeletal Disorders 2007, 8:3 http://www.biomedcentral.com/1471-2474/8/3
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is slowed [16]. Achievement of optimal serum vitamin D
concentrations for maximizing bone strength and
increases in BMD may be required in patients treated with
a bisphosphonate as indicated by our present observa-
tions. It may therefore be important for physicians to dis-
cuss the additional benefits of vitamin D to such patients.
This hypothesis requires further investigations in a pro-
spective controlled trial as there are some limitations to
our study, namely the observational study design and the
lack of longitudinal 25 (OH) vitamin D and PTH concen-
trations during the duration of treatment with bisphos-
phonates.
Bisphosphonates increase BMD by slowing bone turno-
ver, thus allowing secondary mineralisation to progress
leading to increased tissue mineral content [17]. However
there are some uncertainties about whether the long-term
continued mineralisation of older bone increases its
strength [18]. For this reason, the long-term use (> 5
years) of bisphosphonates may be detrimental to the skel-
eton by increasing its brittleness. There is disagreement
whether short periods of 1–2 years off therapy is appropri-
ate after every 5 years of treatment in order to prevent
bone hypermineralisation and reduction in bone
strength. After cessation of bisphosphonates, bone loss
occurs less rapidly compared to other anti-resorptive
agents such as raloxifene or hormone replacement ther-
apy (HRT) [19], although this remains unclear in the case
of Risedronate as the pharmacokinetic properties of this
bisphosphonate may be different to Alendronate's. This is
because some bisphosphonates in particular Alendronate
have a long half-life in bone and may still be biologically
active when bone is remodeled, despite discontinuation
of treatment [20,21]. Allowing a 'wash-out' period of
bisphosphonates from the skeleton may be of clinical
importance, particularly as it is now believed, that long-
term suppression of bone turnover may be harmful to the
skeleton.
The present study suggests that there is good preservation
of BMD at the lumbar spine and total hip following a
short period of discontinuation of bisphosphonates in
long-term users (> 5 years of therapy). Although data were
obtained on a relatively small study population, our find-
ings are similar to those of larger clinical trials [11]. BMD
at the lumbar spine and total hip did not change after 12–
18 months discontinuation of long-term treatment with
either Alendronate or Etidronate, provided vitamin D and
calcium supplementation is adhered to. There is however
less marked preservation of BMD at the femoral neck (FN)
although the values remained higher than at baseline as
previously described [11]. Our data suggest that accumu-
lation of bisphosphonate in bone after long-term use may
result in continued benefits of the drug on BMD, particu-
larly at the spine, after discontinuation for a short period.
There is no difference in BMD changes between patients
who had been on Etidronate or Alendronate.
Conclusion
The present study has highlighted 2 important clinical
issues in the management of post-menopausal osteoporo-
sis in the practical setting of a metabolic bone clinic.
Firstly optimal serum 25 (OH) vitamin D concentrations
of 70 nmol/l or higher may be required for maximizing
the skeletal response to bisphosphonates. Strategies
BMD changes at the femoral neck from baseline in the  patients at and after discontinuation of long-term bisphos- phonates Figure 7
BMD changes at the femoral neck from baseline in the 
patients at and after discontinuation of long-term bisphos-
phonates. A downward trend in FN BMD was observed after 
bisphosphonate withdrawal (* p = 0.094).
Femoral neck BMD (g/cm2) at baseline, at and 
following bisphosphonate discontinuation for 12-18 
months 
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Changes in BMD at the hip following discontinuation of  bisphosphonates for 12–18 months after long-term use Figure 6
Changes in BMD at the hip following discontinuation of 
bisphosphonates for 12–18 months after long-term use.
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should be adopted to increase physicians awareness of the
rationale for ensuring adequate vitamin D status in
women receiving bisphosphonates. Secondly data from
the present study suggest that discontinuation of bisphos-
phonates (Alendronate or Etidronate) for a short period
after long-term treatment, whilst continuing with cal-
cium/vitamin D supplements, does not adversely affect
BMD at the lumbar spine and total hip. However, the
maintenance of BMD after bisphosphonates discontinua-
tion is partial at the femoral neck where a gradual decline
in BMD occurred, although the values remained higher
than at baseline. Close monitoring may be required, par-
ticularly at the femoral neck site and it is important to
ensure compliance with calcium/vitamin D supplements.
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